In this study, we established a noninvasive risk model using a blood IRPS (TMB, TP53, KRAS, EGFR and SMAD4) in Qujing patients with advanced NSCLC to better compensate for the shortfalls of existing prognostic signatures. This evidence concerns the gene EGFR and non-small cell lung carcinoma.